Quantum-Si Inc. Elects New Directors, Reports Compensatory Arrangements
Ticker: QSIAW · Form: 8-K · Filed: May 30, 2024 · CIK: 1816431
| Field | Detail |
|---|---|
| Company | Quantum-Si Inc (QSIAW) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50, $570,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-of-directors, executive-compensation, corporate-governance
TL;DR
Quantum-Si board shakeup: Rothberg & Bernstein in, exec comp details out.
AI Summary
Quantum-Si Incorporated announced on May 27, 2024, a change in its board of directors, with the election of Dr. Jonathan Rothberg and Mr. David Bernstein as Class II directors. The company also reported on compensatory arrangements for its named executive officers. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on executive compensation provide insight into management incentives.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can impact investor confidence and signal potential strategic shifts.
Key Players & Entities
- Quantum-Si Incorporated (company) — Registrant
- Dr. Jonathan Rothberg (person) — Elected Class II Director
- Mr. David Bernstein (person) — Elected Class II Director
- May 27, 2024 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Branford, Connecticut (location) — Business address
FAQ
Who were the individuals elected as Class II directors for Quantum-Si Inc.?
Dr. Jonathan Rothberg and Mr. David Bernstein were elected as Class II directors.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is May 27, 2024.
Under which sections of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the state of incorporation for Quantum-Si Inc.?
Quantum-Si Inc. is incorporated in Delaware.
What information is provided regarding executive compensation?
The filing indicates that it reports on compensatory arrangements of certain officers.
Filing Stats: 1,158 words · 5 min read · ~4 pages · Grade level 10.9 · Accepted 2024-05-30 16:27:01
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share QSI The Nasdaq Stock Mark
- $11.50 — mon stock, each at an exercise price of $11.50 per share QSIAW The Nasdaq Stock Ma
- $570,000 — g an aggregate grant date fair value of $570,000, valued based on a Black Scholes valuat
Filing Documents
- ef20030245_8k.htm (8-K) — 37KB
- ef20030245_ex99-1.htm (EX-99.1) — 14KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-028135.txt ( ) — 237KB
- qsi-20240527.xsd (EX-101.SCH) — 4KB
- qsi-20240527_def.xml (EX-101.DEF) — 18KB
- qsi-20240527_lab.xml (EX-101.LAB) — 27KB
- qsi-20240527_pre.xml (EX-101.PRE) — 20KB
- ef20030245_8k_htm.xml (XML) — 6KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Charles Kummeth to the Board of Directors and Appointment as Chairperson of the Board of Directors On May 27, 2024, the Board of Directors (the "Board") of Quantum-Si Incorporated (the "Company") elected Charles ("Chuck") Kummeth to the Board and appointed him as Chairperson of the Board, each effective as of May 27, 2024 (the "Effective Date"). As of the Effective Date, the Company's current Chairperson of the Board, Jonathan M. Rothberg, Ph.D., continues to serve as a director of the Company but ceased serving as Chairperson of the Board. Mr. Kummeth will serve for a term to continue until the Company's next annual meeting of stockholders. In connection with Mr. Kummeth's appointment to the Board, the Board also approved an increase in the size of the Board from nine to ten members. Mr. Kummeth, age 63, served as the President and Chief Executive Officer of Bio-Techne Corporation ("Bio-Techne") (Nasdaq: TECH) from April 2013 to January 2024, a leading developer and manufacturer of high-quality purified proteins, antibodies, immunoassays, and instruments for biomedical researchers and clinical research laboratories , and currently serves as Senior Advisor to Bio-Techne. Prior to joining Bio-Techne, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. (Nasdaq: TMO) ("Thermo Fisher") from September 2011 to March 2013 . He was President of Thermo Fisher's Laboratory Consumables Division from 2009 to September 2011. Prior to joining Thermo Fisher, Mr. Kummeth served in various roles at 3M Corporation, most recently as the Vice President of the company's Medical Division from 2006 to 2008. Mr. Kummeth also serves on the boards of Bio-Techne, Gentherm Incorporated (Nasdaq: THRM), a thermal management technology company, PerkinElmer Inc., a private life scien
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUANTUM-SI INCORPORATED By: /s/ Christian LaPointe, Ph.D. Name: Christian LaPointe, Ph.D. Title: General Counsel Date: May 30, 2024